Oct. 22 at 8:28 PM
$ONCY In 2025, commercial-stage biotech companies—particularly those in oncology and immunotherapy like Oncolytics Biotech—are typically valued using Enterprise Value-to-Sales (EV/Sales) multiples that range from 4x to 10x annual revenue, depending on product maturity, exclusivity, and competitive positioning.
n summary, active commercial biotechs are generally valued between 5×–10× annual sales, with immuno‑oncology assets at the higher end of that range, particularly when they have limited competition or breakthrough designation prospects. So you do the math simply based on PDAC projected annual sales, then factor in anal, GI, CRC and breast cancer forward sales for ONCY's 'real' valuation level.
